Skip to main content
Daito Pharmaceutical Co., Ltd. logo

Daito Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 4577 ISIN · JP3486150000 T Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2025-03-12 Transaction in Own Shar…
Country JP Japan
Listing T 4577

About Daito Pharmaceutical Co., Ltd.

https://www.eng.daitonet.co.jp/

Daito Pharmaceutical Co., Ltd. is a manufacturer specializing in the integrated production of pharmaceuticals, from active pharmaceutical ingredients (APIs) to finished formulation products. The company's core activities include the development and supply of APIs, primarily for generic drugs, and the manufacturing of generic and over-the-counter (OTC) medications. Additionally, Daito provides contract manufacturing services for various pharmaceutical products. The company emphasizes a comprehensive quality assurance system to ensure the stable supply of high-quality products to its clients.

Recent filings

Filing Released Lang Actions
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document title is "自己株券買付状況報告書（法24条の６第１項に基づくもの）" which translates to 'Report on the Status of Treasury Stock Acquisition (Based on Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act)'. This document details the company's ongoing share repurchase activities during a specific reporting period (February 1 to February 28, 2025). This specific filing relates directly to the company's own shares being transacted, which corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory announcement (RNS), but a specific report on share repurchases.
2025-03-12 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is titled "自己株券買付状況報告書" (Report on the Status of Treasury Stock Acquisition) and explicitly cites the legal basis as "金融商品取引法第24条の6第1項" (Financial Instruments and Exchange Act Article 24-6, Paragraph 1). This type of filing reports on the company's ongoing share repurchase activities during a specific period (January 1, 2025, to January 31, 2025). This directly corresponds to the definition of reporting on the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS). It is not a comprehensive annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a very specific corporate action.
2025-02-13 Japanese
臨時報告書
M&A Activity Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director on January 17, 2025. Section 1 explicitly states the reason for filing: the resolution and execution of a merger agreement (吸収合併) involving a wholly-owned subsidiary, effective June 1, 2025. The filing cites regulations related to timely disclosure (金融商品取引法第24条の５第４項及び企業内容等の開示に関する内閣府令第19条第２項第３号及び第７号の３). This document details a significant corporate action (merger/acquisition) that requires immediate disclosure, fitting the description of a major corporate event filing. In the context of Japanese regulatory filings, this type of report detailing a merger or acquisition of a subsidiary is best classified under the general category for significant corporate actions or regulatory filings. Since the definitions provided do not have a specific code for a Japanese 'Extraordinary Report' (Rinji Hokokusho) detailing a merger, and it is not a standard 10-K, AR, or ER, it falls under the most appropriate general category for significant, non-standard regulatory disclosures. Given the options, 'Regulatory Filings' (RNS) is the best fit for a mandatory, specific disclosure document that doesn't match the other detailed categories (like DIV, CAP, etc.). However, since the content is entirely about a merger/acquisition (TAR), that might be considered, but TAR is defined as 'Merger proposals or takeover bids,' which usually implies an external bid or a more complex M&A scenario. Since this is an internal absorption-type merger of a wholly-owned subsidiary, and it is a formal regulatory filing, RNS (Regulatory Filings) serves as the most accurate catch-all for mandatory, non-standard disclosures not covered elsewhere. Given the detailed nature of the merger information, it is the report itself, not an announcement of a report (RPA). I will classify it as RNS as it is a mandatory regulatory disclosure that doesn't fit the specific M&A (TAR) or Capital (CAP) definitions precisely, although it is related to corporate structure change.
2025-01-17 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains Japanese characters and includes the title "第２四半期報告書" (Second Quarter Report) and references the period "第83期中（自 2024年６月１日 至 2024年11月30日）" (83rd term, from June 1, 2024, to November 30, 2024). It also mentions confirmation by the CEO and CFO regarding the appropriateness of the filing content based on financial instruments laws ("金融商品取引法令"). A comprehensive report for a period shorter than a year (a half-year or quarterly report) corresponds to the Interim / Quarterly Report category. Although the document is short (690 chars) and seems to be a certification/confirmation related to the report, the core subject matter is the 'Second Quarter Report' itself, which is a comprehensive financial report for an interim period. In the context of Japanese filings, this structure often accompanies the actual report or serves as the official certification attached to the comprehensive interim filing. Given the explicit mention of the 'Second Quarter Report' and the confirmation of its contents, the most appropriate classification is the Interim / Quarterly Report (IR), rather than just a publication announcement (RPA), as it contains substantive certification regarding the interim results.
2025-01-10 Japanese
半期報告書－第83期(2024/06/01－2025/05/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Second Quarter Report) for Daito Pharmaceutical Co., Ltd., covering the period from June 1, 2024, to November 30, 2024. It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as required by the Financial Instruments and Exchange Act of Japan. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-01-10 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the company's 82nd Annual General Meeting (AGM) held on August 29, 2024, pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. Section 2 details the resolutions, specifically the election of five directors. This structure—a formal filing reporting the results of a shareholder meeting—aligns perfectly with the definition of reporting AGM results. The closest specific code is AGM-R (AGM Information), which covers presentations and materials shared during the AGM, or DVA (Declaration of Voting Results & Voting Rights Announcements). Since the core content is the official voting results for director elections following the AGM, DVA is the most precise fit for reporting the outcome of the shareholder vote.
2024-09-02 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.